final project sanify

:-

http://www.sanifyhealthcare.com/index.php

ON

“MARKETING AND SALES STRATEGY OF DRUGS OF SANIFY HEALTHCARE PVT.LTD.”

Submitted To:-

Business School of Delhi, Greater Noida -201306

Which is carried out Under the Guidance of

External Guide :- Internal guide:-

Mr. Umesh Chandra ojha Prof. Rajesh kumar

Marketing Head – patna region HOD (Marketing)

Sanify healthcare pvt.ltd. Business School Of Delhi

KUMAR RAJEEV

PGDM (2009-11)

Acknowledgement

I thank Sanify healthcare pvt ltd. for providing all the resources and facilities towards the

successful completion of my project.

My heariest thanks to Mr. Umesh Chandra ojha (regional manager,

marketing , patna) of Sanify healthcare pvt.ltd. for providing me an opportunity and

support without which my project journey would not be so successful. I sincerely thank him

for extending his kind cooperation, able guidance and painstaking efforts in guiding me

throughout the entire phase of my project with his valuable advices, suggestions and

recommendations. He really helped me to understand the marketing strategy and

marketing selling of drugs in domestic market.

I sincerely thank my Internal Guide Prof. Rajesh Kumar for his valuable suggestions and

guidelines.

I acknowledge my sincere thanks to all the faculty members and our friends and family for

rendering me immense facilities and constant support.

Kumar Rajeev

1.Chairman’s message

2.Director’s administrator’s desk

3.About the company

4.Business divisions

5.Company’s vision, mission,& objectives.

6.Development of pharma industries

7.Top ten pharma companies in india.

8.research & development

9.Relationship between pharmaceuticals & biotechnology.

10.Major players in pharma industries.

11.History of sanify healthcare pvt.ltd.

12.Quality process.

13.market share

14.BCG-matrix

15.SWOT analysis

16.product and services

17.Sanative remedies

18.company’s clientele

19.Bibliography.

CHAIRMAN’S MESSAGE The Indian

pharmaceutical industry is one of the largest and most advanced, well recognised industry in the developed countries. The Indian economy is a magnet for the foreign investors. Globalisation has truly integrated the world into a local village and this has made business even more difficult. To cope up in this rapid changing economy, it requires getting competitive in the existing markets with better understanding of existing variables.”Integrate globally, innovate locally’’ has been the need of the hour.

In the modern world of business, it is useless to be a creative original thinker unless you can also sell what you create. Customer satisfaction to customer delightment has been the buzz word for marketers. We at Sanify practice it as our core strength. For this, we ensure that we introduce the latest molecules in the market at competitive rates. There is no greater satisfaction than achieving success through honest dealing and strict adherence to the view that, for you to gain, those you deal with should gain as well. These principles once infused into the business are paramount to reach the ultimate in performance.


Sanify Healthcare Pvt. Ltd. is dedicated in improving the quality of life to fulfill the promise of a healthier world. We ensure that people everywhere have access to safe, effective, innovative medicines at reasonable prices. Each year we add new products in our divisions to help us find solutions to the challenges of today, tomorrow. Further, to solidify our commitment base to our stakeholders, we are building greater transparency and partnering better access to healthcare. We follow an ethical code of conduct and promise to continually improve the way we do business.

“We are what we repeatedly do. Excellence, then, is not an act but a habit’’.

With this note, I would like to wish good luck to the Sanify Family.

My sincere thanks to the Almighty God, for His blessings and paving the way to success for us. I also extend my gratitude to our employees, who are the real source of our dexterity, to the members of the Board for their advice and guidance, and to all our customers, suppliers and well-wishers for their trust, support, confidence and cooperation over the years. As we move ahead, we will be even more determined to capitalize on the new opportunities based on our strong fundamentals of innovation, stability and aggressive marketing. We strongly believe and follow that the secret of a healthy business is honesty and fair dealing. We shall

strive to accomplish our dreams and goals to bring greater effulgence in the future.

ThanK you,

Best wishes

Raj Kumar Verma

It gives me immense pleasure to pen down my views for the current and future scenario of the Pharmaceutical Industry, in perspective of SANIFY’S growth.


The global economy is passing through a complex and challenging phase with some of the world’s largest economies and financial institutions facing unprecedented issues. However, certain timely and decisive actions that are being taken by the governments and industries would help not only moderate the impact but also bring in systemic changes aimed at long term stability.

The pharmaceutical industry is one of the vital sectors in the Indian economy. It is probably ranked next only to the Information Technology industry in terms of potential and degree of technology sophistication. India is gradually positioning itself as a global manufacturing centre for the pharmaceutical industry; its main strengths being low costs allied to excellent production quality, plus highly trained scientific and other staff.

Sanify with its emphasis on New Formulations, and an asset driven growth strategy has competitively positioned itself in the Indian pharmaceutical industry. A strategic focus on niche newer molecules, value chain integration, product versatility, state-of-the-art infrastructure, collaborative partnerships and an empowered organization constitute the key elements of Sanify’s growth model.

Sanify is poised for continued growth with a sustainable strategy anchored on newer formulations and latest

molecules. The Formulation Development department is continuously involved in developing products for the different segments. With several new products being introduced in the anti-diabetic, cardiovascular, Medicines and Surgical segments, the Syntonic division is poised to expand and growth further.

During the year under review, we have established additional business alliances in the ethical marketing adding new products and new regions to existing partnerships. Additional alliance opportunities which add value to the competitive market and provide incremental revenue and profitability opportunities are being pursued. Sanify has successfully pursued an alliance model in the competitive markets with marketing partners who have established market reach and distribution logistics in their markets.

If vision is where the company is going, values tell how the company gets there. Values outline acceptable behavior. We convey values through actions and reactions to others. In fact in Sanify we practice it in our day to day working.

I am confident that with Sanify's experience, technological expertise, knowledge of the pharmaceutical business and able management, we will over time be one of the leading pharmaceutical companies in India.

In Last, but not the least, I thank The Almighty for making us believe that success comes through dedication, commitment and hard work. I also extend my sincere gratitude towards my seniors on the Board for their continued support and wise counsel. The employees at all levels merit highest appreciation for their strong commitment and devotion. I acknowledge the trust of our suppliers, manufacturers and people involved throughout in making the group a success. Their contribution has been as always, significant. My thanks also go to the Distributors/Franchisees/Third parties for their unfailing support, trust and confidence that they have reposed, which will, I am certain, be amply rewarded in the years ahead.

Regards

Surbhi Verma

MORE ABOUT SANIFY HEALTHCARE PVT.LTD.:-

SANIFY HEALTHCARE PVT. LTD.:-

An ISO-9001:2000 certified company, is committed to be a global leader in healthcare. Its divisions-

1STAR BIOMED, SILVER BIOTECH, SANATIVE REMEDIES and SYNTONIC LIFESCIENCES offers multiple arrays of about 543 products covering practically all areas. Directed by conspicious leadership and trained professionals, it is one of the fastest growing pharma companies offering products to prevent, treat and cure challenges in the medical fraternity.

The group has a strong presence in the domestic market and plans to expand in the highly regulated international markets too. Constructing tomorrow’s businesses while simultaneously sustaining excellence in today’s world, demands a delicate balance. It is thus extremely important for the organisation to excel in customer satisfaction. We ensure that our products reach the market in the shortest possible time with the highest level of quality

At Sanify, our experienced professionals steer crucial operational domains like Marketing, Accounts and Finance, Human Resources, Purchase, Graphics and Designing

We listen to our customers and understand their needs and concerns. Based on the requirements, we offer a comprehensive set of services which include, Formulation and Process, Products Approval and search of Brand Names, Designing Printing, Visual-Aid and Promotional Material etc. under one roof.

The company manufactures its products in Himachal Pradesh, which is an excise free zone. We offer franchisee on monopoly basis nationwide. With a wide product range, we have franchisees appointed in almost every state. After years of satisfaction, trust and support of our customers, the group has established itself as strong brand in the market. We strive to provide total commitment to healthcare to achieve leadership in chosen markets. With the latest formulations in the medical world, we are also offering the most innovative combinations at reasonable prices to fulfill the dream of healthier lives. We also provide attractive packaging and promotional materials based on the customer’s requirements.

We are also engaged in third party manufacturing for tablets, capsules, injections, ointments, nasal drops, liquids, dry syrups, protein powders and many more entities at marginal prices. We provide you various services including formulation, designing, printing and labeling under one roof. We ensure to provide you the best services at minimum possible time. We adjust and adapt to the changing needs of our customers and remain dedicated

in our efforts to serve them to the best of our ability.

We enjoy an excellent credibility among our esteemed customers, who know that our Experience, Expertise and Enterprise are always at their disposal. An unflinching commitment to quality is our promise to you. We are able to guarantee that our products meet the highest quality parameters that you expect from us.

We understand our commitment and responsibility towards the stakeholders of Sanify Group. We are building an empowered and ethical Sanify Family to strengthen the foundation for a bright future. We are embarked with the tools of foresight, strategy and quality personnel to focus on brand building.

We endeavour to be one of the most competitive company in the industry with emphasis on efficiency in operations, reliability for customers, affordable prices, timely delivery and thrust on introduction of new molecules in the marketplace.

Our core strength lies in our dream to help people live longer and healthier lives. In pursuit of this concern, we are primarily focusing on creating new value and benefiting to the enrichment of society through our business.



BUSINESS DIVISIONS:-

In pursuit of excellence, SANIFY HEALTHCARE is forging into high class quality and affordable healthcare, constantly laying emphasis on customer satisfaction and confidence through its five divisions. The company is also accredited with ISO 90012000 certification.-

The group has 6 independent divisions each having a unique product range. We appoint Area Managers and Franchisees depending upon their area of operations. The company has formed its market network by appointing these marketing distributors/franchisees with monopoly rights. We also provide all kinds of promotional inputs and marketing support to its customers.

The rates and packing of drugs is revised from time to time as per the government regulations. We add latest molecules in our product list depending upon market requirements. Our products are strictly in compliance with the quality parameters at very competitive rates.

Vision: - Our vision is to be a key global pharma company with increasing focus on ethics, innovative research, unmatched quality and service through affordable and accessible healthcare.

Mission: -

To create a customer centric culture by


improving health care needs through quality, integrity and creativity.

Objective:- The basic objective of the company is to manufacture its own products as well as to manufacture the products on third party basis at competitive prices.

DEVELOPMENT OF PHARMACEUTICAL INDUSTRIES :-

The Indian pharmaceutical industry is the world's third-largest by volume and is likely to lead the manufacturing sector of India

India's bio-tech industry clocked a 17 percent growth with revenues of Rs.137 billion ($3 billion) in the 2009-10 financial year over the previous fiscal. Bio-pharma was the biggest contributor generating 60 percent of the industry's growth at Rs.8,829 crore, followed by bio-services at Rs.2,639 crore and bio-agri at Rs.1,936 crore.

The first pharmaceutical company are Bengal Chemicals and Pharmaceutical Works, which still exists today as one of 5 government-owned drug manufacturers, appeared in Calcutta in 1930.

For the next 60 years, most of the drugs in India were imported by multinationals either in fully-formulated or bulk form. The government started to encourage the growth of drug manufacturing by Indian companies in the early 1960s, and with the Patents Act in 1970, enabled the industry to become what it is today.

This patent act removed composition patents from food and drugs, and though it kept process patents, these were shortened to a period of five to seven years. The lack of patent protection made the Indian market undesirable to the multinational companies that had dominated the market, and while they streamed out, Indian companies started to take their places.

They carved a niche in both the Indian and world markets with their expertise in reverse-engineering new processes for manufacturing drugs at low costs. Although some of the larger companies have taken baby steps towards drug innovation, the industry as a whole has been following this business model until the present.

In 2002, over 20,000 registered drug manufacturers in India sold $9 billion worth of formulations and bulk drugs. 85% of these formulations were sold in India while over 60% of the bulk drugs were exported, mostly to the United States and Russia.

Most of the players in the market are small-to-medium enterprises; 250 of the largest companies control 70% of the Indian market. Thanks to the 1970 Patent Act, multinationals represent only 35% of the market, down from 70% thirty years ago.

Most pharma companies operating in India, even the multinationals, employ Indians almost exclusively from the lowest ranks to high level management. Mirroring the social structure, firms are very hierarchical.

TOP TEN PHARMACEUTICAL COMPANY OF INDIA:-

Homegrown pharmaceuticals, like many other businesses in India, are often a mix of public and private enterprise. Although many of these companies are publicly owned, leadership passes from father to son and the founding family holds a majority share.

In terms of the global market, India currently holds a modest 1-2% share, but it has been growing at approximately 10% per year.

India gained its foothold on the global scene with its innovatively-engineered generic drugs and active pharmaceutical ingredients (API), and it is now seeking to become a major player in outsourced clinical research as well as contract manufacturing and research.

There are 74 U.S. FDA-approved manufacturing facilities in India, more than in any other country outside the U.S, and in 2005, almost 20% of all Abbreviated New Drug Applications (ANDA) to the FDA are expected to be filed by Indian companies[21,27]. Growth in other fields notwithstanding, generics are still a large part of the picture. London research

CompanyRevenue 2008 (Rs crore)

Revenue 2008 (USD millions)

Ranbaxy Laboratories 4,461 1,026

Dr. Reddy's Laboratories 1,933 444

Cipla 1,842 423

Nicholas Piramal 1,387 319

Aurobindo Pharma 1,260 290

GlaxoSmithKline 1,228 282

Lupin Laboratories 1,180 271

Sun Pharmaceutical Industries 1,110 255

Cadila Healthcare 1,091 251

Wockhardt 980 225

company Global Insight estimates that India’s share of the global generics market will have risen from 4% to 33% by 2007.

Product development:-

Companies are also starting to adapt their product development processes to the new environment. For years, firms have made their ways into the global market by

researching generic competitors to patented drugs and following up with litigation to challenge the patent.

This approach remains untouched by the new patent regime and looks to increase in the future. However, those that can afford it have set their sights on an even higher goal: new molecule discovery.

Although the initial investment is huge, companies are lured by the promise of hefty profit margins and the recognition as a legitimate competitor in the global industry. Local firms have slowly been investing more money into their R&D programs or have formed alliances to tap into these opportunities.

Small and medium enterprises:-

As promising as the future is for a whole, the outlook for small and medium enterprises (SME) is not as bright.

The excise structure changed so that companies now have to pay a 16% tax on the maximum retail price (MRP) of their products, as opposed to on the ex-factory price. Consequently, larger companies are cutting back on outsourcing and what business is left is shifting to companies with facilities in the four tax-free states - Himachal Pradesh, Jammu & Kashmir, Uttaranchal and Jharkhand.

As SMEs wrestled with the tax structure, they were also scrambling to meet the July 1 deadline for compliance with the revised Schedule M Good Manufacturing Practices (GMP). While this should be beneficial to consumers and the industry at large, SMEs have been finding it difficult to find the funds to upgrade their manufacturing plants, resulting in the closure of many facilities.

Others invested the money to bring their facilities to compliance, but these operations were located in non-tax-free states, making it difficult to compete in the wake of the new excise tax.

Challenges:-

All of these changes are ultimately good for the Indian pharmaceutical industry, which suffered in the past from inadequate regulation and large quantities of spurious drugs. They force the industry to reach a level necessary for global competitiveness. However, they have also exposed some of the inadequacies in the industry today.

Its main weakness is an underdeveloped new molecule discovery program. Even after the increased investment, market leaders such as Ranbaxy and Dr. Reddy’s Laboratories spent only 5-10% of their revenues on R&D, lagging behind Western pharmaceuticals like Pfizer, whose research budget last year was greater than the combined revenues of the entire Indian pharmaceutical industry.

This disparity is too great to be explained by cost differentials, and it comes when advances in genomics have made research equipment more expensive than ever.

The drug discovery process is further hindered by a dearth of qualified molecular biologists.

REEARCH & DEVELOPMENT:-

Both the Indian central and state governments have recognized R&D as an important driver in the growth of their pharma businesses and conferred tax deductions for expenses related to research and development.

They have granted other concessions as well, such as reduced interest rates for export financing and a cut in the number of drugs under price control. Government support is not the only thing in Indian pharma’s favour, though; companies also have access to a highly-developed IT industry that can partner with them in new molecule discovery.

Labor force:-

India’s greatest strengths lie in its people. India also boasts a cheap, well-educated, English-speaking labor force that is the base of its competitive advantage.

Although molecular biologists are in short supply, there are a number of talented chemists who are equally as important in the discovery process.

In addition, there has been a reverse brain-drain effect in which scientists are returning from abroad to accept positions at lower salaries at Indian companies. Once there, these foreign-trained scientists can transfer the benefits of their knowledge and experience to all of those who work with them.

India’s wealth of people extends benefits to another part of the drug commercialization process as well. With one of the largest and most genetically diverse populations in any single country, India can recruit for clinical trials more quickly and perform them more cheaply than countries in the West. Indian firms have just recently started to leverage.

BIOTECHNOLOGY:-

Relationship between pharmaceuticals and biotechnology:-

Unlike in other countries, the division between biotechnology and pharmaceuticals remains fairly defined in India.

Biotech there still plays the role of pharma’s little sister, but many outsiders have high expectations for the future. India accounted for 2% of the $41 billion global biotech market and in 2003 was ranked 3rd in the Asia-Pacific region and 11th in the world in number of biotechs.

In 2004-5, the Indian biotech industry saw its revenues grow 37% to $1.1 billion.[2,9] The Indian biotech market is dominated by biopharmaceuticals; 75% of 2004-5 revenues came from biopharmaceuticals, which saw 30% growth last year. Of the revenues from biopharmaceuticals, vaccines led the way, comprising 47% of sales. Biologics and large-molecule drugs tend to be more expensive than small-molecule drugs, and India hopes to sweep the market in biogenerics and contract manufacturing as drugs go off patent and Indian companies upgrade their manufacturing capabilities.

Top 20 Biotechnology Companies in India, 2004:-Rank Company Revenue 2004 (Rs crore) Revenue 2004 (USD millions)

1 Biocon 646 148.6

2Serum Institute of India

565 129.9

3 Panacea Biotec 217 50.0

4Venkateshwara Hatcheries

188 43.2

5Mahyco Monsanto

166 38.3

6 Novo Nordisk 135 31.0

7 Rasi Seeds 87 20.08 Aventis Pharma 84 19.49 Bharat Serums 81 18.6

10Chiron Behring Vaccines

78 17.9

11 GlaxoSmithKline 78 17.9

12Indian Immunologicals

72 16.6

13Shantha Biotechnics

70 16.1

14 Novozymes 69 15.9

15Eli Lilly and Company

68 15.7

16 Wockhardt 67 15.4

17Bharat Immunological & Biological Corp.

53 12.3

18Bharat Biological International

41 9.4

19Advanced Biochemicals

40 9.1

20 Biological E 36 8.3USD 1 = Rs 43.5

Most companies in the biotech sector are extremely small, with only two firms breaking 100 million dollars in revenues.

At last count there were 265 firms registered in India, over 75% of which were incorporated in the last five years. The newness of the companies explains the industry’s high consolidation in both physical and financial terms.

Almost 50% of all biotechs are in or around Bangalore, and the top ten companies capture 47% of the

market.

The top five companies were homegrown; Indian firms account for 62% of the biopharma sector and 52% of the industry as a whole.The Association of Biotechnology-Led Enterprises (ABLE) is aiming to grow the industry to $5 billion in revenues generated by 1 million employees by 2009, and data from the Confederation of Indian Industry (CII) seem to suggest that it is possible.

Comparison with the U.S.:-

The Indian biotech sector parallels that of the U.S. in many ways. Both are filled with small start-ups while the majority of the market is controlled by a few powerful companies.

Both are dependent upon government grants and venture capitalists for funding because neither will be commercially viable for years. Pharmaceutical companies in both countries have recognized the potential effect that biotechnology could have on their pipelines and have responded by either investing in existing start-ups or venturing into the field themselves.

In both India and the U.S., as well as in much of the globe, biotech is seen as a hot field with a lot of growth potential

Relationship with IT:-

Many analysts have observed that the hype around the biotech sector mirrors that of the IT sector. Biotech colleges have been popping up around the country eager to service the pools of students that want to take advantage of a growing industry.

The International Finance Commission, the private investment arm of the World Bank, called India the “centerpiece of IFC’s global biotech strategy.”

Of the $110 million invested in 14 biotech projects investment globally, the IFC has given $43 million to 4 projects in India.

According to Dr. Manju Sharma, former director of the Department of Biotechnology, the biotech industry could become the “single largest sector for employment of skilled human resource in the years to come.”

British Prime Minister Tony Blair was similarly impressed, citing the success of India’s biotech industry as the reason for his own country’s own biotech opportunities.

Malaysia is also looking to India as an example for growing its own biotech industry.

Government support:-

The Indian government has been very supportive. It established the Department of Biotechnology in 1986 under the Ministry of Science and Technology.

Since then, there have been a number of dispensations offered by both the central government and various states to encourage the growth of the industry.

India’s science minister launched a program that provides tax incentives and grants for biotech start-ups and firms seeking to expand and establishes the Biotechnology Parks Society of India to support ten biotech parks by 2010. Previously limited to rodents, animal testing was expanded to include large animals as part of the minister’s initiative.

States have started to vie with one another for biotech business, and they are offering such goodies as exemption from VAT and other fees, financial assistance with patents and subsidies on everything ranging from investment to land to utilities.

Foreign investment:-

The government has also taken steps to encourage foreign investment in its biotech sector. An initiative

passed earlier this year allowed 100% foreign direct investment without compulsory licensing from the government1.

In April, a delegation headed by the Kapil Sibal, the minister of science and technology and ocean development, visited five cities in the U.S. to encourage investment in India, with special emphasis on biotech. Just two months later, Sibal returned to the U.S. to unveil India’s biotech growth strategy at the BIO2005 conference in Philadelphia.

Challenges:-

The biotech sector faces some major challenges in its quest for growth. Chief among them is a lack of funding, particularly for firms that are just starting out.

The most likely sources of funds are government grants and venture capital, which is a relatively young industry in India. Government grants are difficult to secure, and

due to the expensive and uncertain nature of biotech research, venture capitalists are reluctant to invest in firms that have not yet developed a commercially viable product.

As previously mentioned, India hopes to solve its funding problem by attracting overseas investors and partners. Before these potential saviors will invest significant sums in the industry, however, there needs to be better scientific and financial accountability. India is slowly working towards these goals, but it will be a while before they are up to the standards of Western investors.

India’s biotech firms share another problem with their pharmaceutical cousins: a lack of qualified employees. Biotech has the additional disadvantage of competing against IT for ambitious, science-minded students but not being able to guarantee the same compensation.

An aspiring researcher in India needs 7–10 years of education covering a range of specialties in order to qualify to work in biotech. Even if a student does choose to go on the biotech path, the ineffectual curriculum at many universities makes it doubtful as to whether he will be qualified to work in the field once finished.

One estimate shows that 10% of upper-echelon biotech recruits have come from foreign countries. While this is not a problem, per se, it drives up cost in a country whose competitive advantage is based on cheap, high-quality labor. Far from ending with scientists, there is also a shortage of people with a knowledge of biotechnology in related fields: doctors, lawyers, programmers, marketing personnel and others.

While little has been done about the latter half of the employee crunch, the government has addressed the problem of educated but unqualified candidates in its Draft National Biotech Development Strategy. This plan included a proposal to create a National Task Force that would work with the biotech industry to revise the curriculum for undergraduate and graduate study in life sciences and biotechnology.

The government’s strategy also stated intentions to increase the number of PhD Fellowships awarded by the Department of Biotechnology to 200 per year. These human resources will be further leveraged with a “Bio-Edu-Grid” that will knit together the resources of the academic and scientific industrial communities, much as they are in the U.S.

MAJOR PLAYER OF THIS FIELD:-

Ranbaxy Laboratories :-

Sri S T Kalairaj, Chairman

Ranbaxy is the leader in the Indian pharmaceutical market, taking in $1.174 billion in revenues for a net profit of $160 million in 2004.

It was the first Indian pharmaceutical to have a proprietary drug (extended-release ciprofloxacin, marketed by Bayer) approved by the U.S. FDA, and the U.S. market accounts for 36% of its sales. 78% of Ranbaxy’s sales are from overseas markets; its offices in 44 countries manage manufacturing in 7 countries and distribution in over 100.

IMS Health estimated that Ranbaxy is among the top 100 pharmaceuticals in the world and that it is the 15th fastest growing company. By 2012, Ranbaxy hopes to be one of the top 5 generics producers in the world, and it consolidated its position with the purchase of French firm RGP Aventis in 2003.

Ranbaxy also has higher aspirations, however, “to build a proprietary prescription business in the advanced markets.” To this end, it keeps a dedicated research facility in Gurgaon staffed with over 1100 scientists. They currently have two molecules in Phase II trials and 3-5 in pre-clinical testing. It spent $75 million in R&D in 2004, a 43% increase over its 2003 expenditure.

CEO Brian Tempest is the only non-Indian on the senior management team.

Dr. Reddy's Laboratories K. Anji Reddy, Chairman

Founded in 1984 with $160,000, Dr. Reddy’s was the first Asia-Pacific pharmaceutical outside of Japan and the sixth Indian company to be listed on the New York Stock Exchange.

It earned $446 million in fiscal year 2005, deriving 66% of this income from the foreign market. In order to strengthen its global position, Dr. Reddy acquired UK-based BMS Laboratories and subsidiary Meridian Healthcare.

Although 58% of Dr. Reddy’s revenues come from generic drugs, the company was committed to

WTO-compliance long before the 2005 bill took effect, and most of these products were already off patent. Dr. Reddy has long been a research-oriented firm, preceding many of its peers in setting up a New Drug Development Research (NDDR) in 1993 and out-licensing its first compound just four years later. Dr. Reddy’s has since outlicensed two more molecules and currently has three others in clinical trials.

Although Dr. Reddy’s is publicly-traded, the Reddy family (including founder/chairman K. Anji Reddy, son-in-law/CEO GV Prasad and son/COO Satish Reddy) holds a hefty 26% share in the company.11,44

Nicholas Piramal :-{Asish Mishra, Chairman }

Now a company grossing $350 million per year, Nicholas Piramal started its existence with the 1988 acquisition of Nicholas Laboratories and grew through a series of mergers, acquisitions and alliances. The company has formed a name for itself in the field of custom manufacturing. It cites its 1700-person global sales force as another core strength; with its acquisition of Rhodia’s inhalation anaesthetics business, Nicholas Piramal gained a sales and marketing network spanning 90 countries34.

Nicholas Piramal is well-poised for the challenge of surviving in the aftermath of product patent protection. The company has respected intellectual property rights

since its inception and refused to "support generic companies seeking first-to-file or early-to-market strategies." Instead, it decided to make its own intellectual property and opened a research facility last November in Mumbai with hopes of launching its first drug in 2010 at a cost of $100,000.

Cipla :-Dr. Yusuf K. Hamied, Chairman and Managing Director

Cipla burst into the international consciousness in 2000 with Triomune, an AIDS treatment costing between $300 and $800 per year that infringed upon patents held by several companies who were selling the cocktail for $12,000 per year.

Long before this news, Cipla had been building a strong global presence, and it now distributes its 800-odd products in over 140 countries.

Privately-held Cipla holds a prominent spot in its home country as well; it is the leader in domestic sales, having just unseated GlaxoSmithKline for the first time in 28 years. Revenue in 2004 totaled $552 million (using Rs 43.472 = $1) about 75% of which was derived in India. Cipla did not report having a research program.

Biocon :-{Dr. Kiran Mazumdar-Shaw, Chairman and Managing Director} :-

Originally an extension to an Irish chemicals company seeking to break into the Indian market, Biocon is now the leading biotech in India, bringing in Rs 646.36 crore (almost $150 million) in revenue for fiscal year 2004. It initially made its money by producing enzymes, but Biocon recently decided to become a research-oriented company with the goal of bringing a proprietary new drug to market.

The company went public in March 2004, and "its shares were oversubscribed by 33 times on opening day." Eight months later it launched Insugen, a bio-insulin that is its first branded product. Biocon also has two wholly-owned subsidiaries, Syngene and Clinigene, that perform custom research and clinical trials.

Serum Institute of India:- Dr. Cyrus Poonawalla, Chairman

The Serum Institute of India can make the enviable claim that 2 out of every 3 children in the world are immunized with one of their vaccines. It is the world’s largest producer of measles and DTP vaccines, and its portfolio includes other vaccines, antisera, plasma products and anticancer compounds. The Serum Institute earned Rs 565 crore ($130 million) in revenue in fiscal year 2005, selling mainly to UN agencies and to the Indian government. The Serum Institute is part of the Poonawalla Group, whose holdings include a horse stud farm and manufacturers of industrial equipment and components.1,4,40

Other important domestic companies

Nectar Lifesciences [4] Mr. Sanjiv Goyal, Chairman

Macleods Pharma [5] Dr. Rajendra Agarwal, Managing Director

Intas Biopharmaceuticals Dr. Urmish Chudgar, Managing Director

Bharat Serums [6] Mr. Bharat V. Daftary, Chairman and Managing Director

Lupin Laboratories Dr. Desh Bandhu Gupta, Chairman

Orchid Pharmaceuticals Mr. R. Narayanan, Chairman

Panacea Biotech [7] Mr. Soshil Kumar Jain, Chairman

Sun Pharmaceuticals Dilip S. Sanghvi, Chairman and Managing Director

Torrent Pharmaceuticals Sudir Mehta, Chairman

Wockhardt Habil F. Khorakiwala, Chairman

Cadila Healthcare

Pankaj R. Patel, Chairman and Managing Director

Hetero Drugs Dr. B. Partha Saradhi Reddy, Chairman and Managing Director

K. A. Malle Pharmaceuticals Limited [8]

AMN Pharmaceuticals [9] Amndip, Chairman and Managing Director

Ajanta Pharma [10] Yogesh Agrawal, Managing Director

Green Apple Lifesciences Limited [11] Mitesh Mehta, Chairman

Relaince Life Sciences Pvt Ltd [12] Mr. K.V. V. Subramaniam, President and CEO

Sanify Health Care LTD.CHAIRMAN, Raj Kumar Verma

OUR HISTORY SANIFY, as the name suggests, means” to improve health”. It was the vision of Mr. Sachin Verma, Managing Director, to achieve leadership through quality and world class services. He recognised the imperative to become more creative, customer centric and collaborative. He adopted a response driven strategy by assessing response from the doctors, wholesalers, retailers and representatives in local markets of North India. Extending his area of operations to nearby markets, he created a strong team of experienced professionals whose ideas and vision helped to build dependable business relationships.

He exemplified effective leadership behaviour and floated SANIFY HEALTHCARE PVT. LTD. in 2003. He focused on changes in market and customer demands, thereby resulting in a multi-product portfolio covering practically all areas. It received


tremendous response from the customers owing to its quality, services and wide product range at reasonable prices. It differentiated itself from the existing players by addressing to virtue, excellence, ambition and responsibility.

It came up further with new divisions: STAR BIOMED, SILVER BIOTECH, SANATIVE REMEDIES to serve the medical fraternity with latest molecules. An unflinching commitment to quality has been the promise of the company. As per the requirements of the customers, it offered a wide range of services under one roof. After the success of these divisions and trust, support of the customers, it proudly announced the launch of its fifth division- SYNTONIC LIFESCIENCES in the year 2008 and sixth division SUCCESS PHARMACEUTICALS in the year 2009.

All the divisions covered a wide range including the latest combinations in the market place. Also it was a one stop place for all the products and services. The success earmarked the growth prospects of the group as well as its customers who dedicatedly promoted the brand in their targeted markets. The achievement of the company was clearly visible from its huge satisfied customer base which is the real testimony.

The company was also successful in mapping out an ambitious programme with intelligent direction to establish its strong presence in the domestic market and further extending itself across

the international boundaries. It followed an ethical code of conduct and strived for improving the healthcare needs through quality and right pricing. The eminence of the group began as the dream of one man transformed into the dream of many.

Our quality policy is to manufacture pharmaceutical formulations keeping with the most stringent international standards while complying strictly with product license stipulations. This quality policy is communicated and understood at appropriate levels.

At Sanify, we are deeply committed to excellence and quality. We realize the critical importance of QUALITY CONTROL and ASSURANCE. QUALITY Our quality assurance system ensures that not even a single detail is missed out. Right from purchasing the best quality raw material to best processing and packaging, we take utmost care.

The manufacturing is also done under high degree of surveillance to ensure health concerns of millions of

people we serve. All our products carry an authentic test report conducted from an authorised laboratory/test centre.

In a nutshell, all that can be said is 'write down what you do, do what is written down'!

BCG Growth-Share Matrix

Position of this company that is sanify healthcare pvt.ltd. in bcg matrix is probably in cash cow.This is due to high market share and low growth. Dogs - Dogs have low market share and a low growth rate and thus neither generate nor consume a large amount of cash. However, dogs are cash traps because of the money tied up in a business that has little potential. Such businesses are candidates for divestiture.

Question marks - Question marks are growing rapidly and thus consume large amounts of cash, but because they have low market shares they do not generate much cash. The result is a large net cash comsumption. A question mark (also known as a "problem child") has the potential to gain market share and become a star, and eventually a cash cow when the market growth slows. If the question mark does not succeed in becoming the market leader, then after perhaps years of cash consumption it will degenerate into a dog when the market growth

declines. Question marks must be analyzed carefully in order to determine whether they are worth the investment required to grow market share.

Stars - Stars generate large amounts of cash because of their strong relative market share, but also consume large amounts of cash because of their high growth rate; therefore the cash in each direction approximately nets out. If a star can maintain its large market share, it will become a cash cow when the market growth rate declines. The portfolio of a diversified company always should have stars that will become the next cash cows and ensure future cash generation.

Cash cows - As leaders in a mature market, cash cows exhibit a return on assets that is greater than the market growth rate, and thus generate more cash than they consume. Such business units should be "milked", extracting the profits and investing as little cash as possible. Cash cows provide the cash required to turn question marks into market leaders, to cover the administrative costs of the company, to fund research and development, to service the corporate debt, and to pay dividends to shareholder.

SWOT ANALYSIS:-

Strength of the Company:-

Long experience in the DRUG manufacturing business.Ability to absorb technology, develop processes for new products and commercialize them.Rapidly expanding into the manufacture of many other critical Industrial Chemicals.Fastest emerging pharma company.Wide distribution network in India.

Weakness of the Company:-

They not utilize the 100% of their production capacity.

Lacking some marketing strategy to increase market share.

Failure in retaining old customers.

Opportunity for the Company:-

….product of this company is very cheap and effective.…. With huge investment in infrastructure and construction the demand of paints also increases.

Threat for the company :-

..There are a number of competitors in this competitive market.

PRODUCTS:-

At SANIFY, we have a diverse multitude of products to deliver care for our FRANCHISEES. Through our scorching expansion plans; we continue to retain the focus on quality at affordable prices and quick delivery. We offer injectables, tablets,capsules, liquids, dry syrups, mouth wash, protein powder, soaps, shampoos, eye/ear/nasal drops, ointments, toothpaste and many more products at very attractive packaging. We offer our maximum range in blister and alu-alu packaging.We provide liquids in sterilised pet bottles with attractive packaging. We have the entire range of uncoated, sugar coated, enteric coated, film coated, chewable, lozenges,

sustained release and dispersible tablets .

Our divisions cover practically all products with a range of almost 250 products in each division. We add to our list the latest combinations as per the market requirements.The company also provides wide range of promotional materials including visual aids, product cards, MR bags, leave-behind cards, catch covers, detailing story, order books, visiting cards, stickers, reminder cards,manuals and attractive gift items as per the requirements of the franchisee who are given exclusive monopoly rights to market our highly competitive product range.

SERVICES:-

SANIFY HEALTHCARE is one stop shop for your entire set of services for THIRD PARTY MANUFACTURING. In this case, we assist our customers in Brand name searching. Designing, Printing, Economical raw materials purchases and search for manufacturing units following ISO-WHO-GMP norms. We also provide latest clinical references and drug comparisons at your doorstep.

We welcome third parties and deliver products under their given brand names. Big and even small batch sizes can be made depending upon the requirements at lowest possible prices.

We also assist you in providing promotional inputs to your customers at attractive rates.

The company offers flexible terms of trade and gives each customer personal attention. We promise you of our quality as well as reliable assistance.

Kindly contact us for your requirements and enable us to give you our best rates and services.

ALIMENTARY SYSTEM

S.No COMPOSITIONS Type PACK Packing1 Ciprofloxacin 500mg + Tinidazole 600mg Tablet 10x10 Blister2 Fungal Diastase 50mg +Pepsin 10mg Syrup 200ml Bottle

3

Fructooligosaccharide 200mg + L-Glutamine 100mg + Bifidobacterium Bifidum 150 Million Spores + Bifidobacterium Longum 150 Million Spores + Lactobacillus Acidophilus 300 Million Spores + Stereptococcus Thermophilus 150 Million Spores

Capsules 10x10 Alu Alu

4 Lactulose 10gm/15ml Solution 100 ml Bottle5 Magaldrate 400mg + Simethicone 20mg /5ml Suspension170 ml Bottle6 Ofloxacin 50 mg + Tinidazole 150 mg Suspension30ml Bottle

7 Omeprazole 20 mg Capsules 10X10Strip Pack

8 Omeprazole 20mg + Domperidone 10mg Capsules 10X10Strip Pack


9 Pantoprazole 40 mg Tablet 10X10 Alu Alu

10 Pantoprazole 40 mg Injection1X40 mg

Vial

11

Probiotics 325 (Lactobacillus Acidophilus Lactobacillus, Rhamnosus, Bifidobacterium Bididus, Bifidobaacterium Longum, Streptococcus Boulardil) + Fructo Oligosaccharide 100mg + Fungal Amylase 50mg

Capsules 1x6Strip Pack

12 Rabeprazole 20 mg Tablet 10X10 Alu Alu13 Rabeprazole 20 mg + Domperidone 10 mg Tablet 10X10 Alu Alu14 Rabeprazole 20 mg + Domperidone 30 mg SR Capsules 10X10 Alu Alu

15 Rabeprzaole 20mg (EC) + Itopride SR 150mg Capsules 10 x 10Strip Pack

16 Rabeprazole 20mg Injection1X20 mg

Vial

17 Sucralfate 1gm + Oxetacaine 20mg/10 ml Suspension100ml Bottle

ANTI- ALLERGICS

S.No COMPOSITIONS Type PACK Packing

1Cetirizine 2.5mg + Paracetamol 125mg + Phenylpropanolamine 12.5mg

Suspension

60ml Bottle

2Cetirizine 5mg + Paracetamol 500mg +Phenylpropanolamine Hcl 25 mg

Tablet 10X10 Alu Alu

3 Cetirizine Dihydrochloride 10 mg Tablet 10X10 Alu Alu4 Fexofenadine 120mg Tablet 10 x 10 Blister

5Levocetirizine 5mg +Paracetamol 500 mg+ Phenylpropanolamine Hcl 25mg


6 Levocetirizine Dihydrochloride 5mg Tablet 10X10 Alu Alu7 Loratadine 10mg Tablet 10X10 Alu Alu

8Paracetamol 500mg + Phenylpropanolamine Hcl 10mg + Chlorpheniramine Maleate 2mg + Caffeine 30mg

Tablet 10x10 Blister

ANTIBIOTICS

S.No

COMPOSITIONS Type PACK Packing

1 Acyclovir 200mg Tablet 10 x 10 Blister

2 Acyclovir 800mg Tablet 10 x 10 Blister

3 Albendazole 200mg /5mlSuspension

15ml Bottle

4 Albendazole 400mg Tablet 1x1 Blister

5 Arteether 75mg/ml Injection 3x1mgAmpoule

6 Arteether 150 mg/2ml Injection 3x2mlAmpoule

7 Amikacin 100 mg Injection 1X100mgAmpoule

8 Amikacin 250 mg Injection 1X250 mgAmpoule

9 Amikacin 500 mg Injection 1X500mgAmpoule

10Amoxycillin 1 gm + Clavulanate Potassium 200mg

Injection 1X1.2 gm Vial

11Amoxycillin 200mg + Clavulanic Acid 28.5mg

Dry Syrup 30ml Bottle

12 Amoxycillin 250mg + Di-Cloxacillin 250mg Capsules 10X10 Alu Alu

13Amoxycillin 250mg + Clavulanic Acid 125mg

Tablet 10 x 10 Alu Alu

14 Amoxycillin 250mg DT Tablet 10 x 10 Alu Alu15 Amoxycillin 500mg + Clavulanic Acid 125mg Tablet 3X10 Alu Alu16 Artesunate 50mg Tablet 1x4 Blister17 Artesunate 60mg Injection 1x60 mg Vial

18 Azithromycin 200mg / 5mlSuspension

15ml Bottle

19 Azithromycin 250 mg Tablet 3x10 Alu Alu20 Azithromycin 500 mg Tablet 10x10 Alu Alu21 Cefaclor 125mg/5ml Dry Syrup 30ml Bottle22 Cefepime 1Gm Injection 1X1000 mg Vial23 Cefixime 100 mg Tablet 10X10 Alu Alu24 Cefixime 200 mg Tablet 10X10 Alu Alu

25 Cefixime 200mg + Clavulanate 125mg Tablet 1x4Strip Pack

26 Cefixime 50mg / 5ml Dry Syrup 30ml Bottle27 Cefixime 50mg + Clavulanate 31.25mg Dry Syrup 30ml Bottle

28 Cefoperazone 1Gm Injection 1000 mg Vial29 Cefoperazone 500mg + Sulbactam 500 mg Injection 1X1 gm Vial

30Cefpodoxime 200mg + Clavulanic Acid 125mg

Tablet 3x10Strip Pack

31 Cefpodoxime Proxetil 100mg Tablet 10X10 Alu Alu32 Cefpodoxime Proxetil 200 mg Tablet 3X10 Alu Alu33 Cefpodoxime Proxetil 50 mg/5ml Dry Syrup 30ml Bottle34 Ceftazidime 250 mg Injection 1X250 mg Vial35 Ceftazidime 1000 mg Injection 1X1000 mg Vial36 Ceftriaxone 125 mg Injection 1X125mg Vial37 Ceftriaxone 250 mg Injection 1X250mg Vial38 Ceftriaxone 500 mg Injection 1X500mg Vial39 Ceftriaxone 1 gm Injection 1X1 gm Vial40 Ceftriaxone 250 mg+ Sulbactam 125 mg Injection 1X375mg Vial41 Ceftriaxone 500 mg+ Sulbactam 250 mg Injection 1X750mg Vial42 Ceftriaxone 1 gm+ Sulbactam 500 mg Injection 1X1.5 gm Vial

43 Ceftriaxone 250mg +tazobactam 31.25mg Injection1x281.25mg

Vial

44Ceftriaxone 500mg + Tazobactam Sodium 62.5mg

Injection 1x562.5mg Vial

45 Ceftriaxone 1gm + Tazobactam 125 mg Injection 1X1125mg Vial46 Cefuroxime 125 mg/5ml Dry Syrup 30ml Bottle47 Cefuroxime 250 mg Tablet 10X10 Alu Alu

48 Cefuroxime 500 mg Tablet 4X10Strip Pack

49 Cefuroxime 750mg Injection 1x750mg Vial50 Ciprofloxacin 500 mg Tablet 10X10 Blister51 Fluconazole 150 mg Tablet 1x1 Blister52 Gatifloxacin 400 mg Tablet 10X10 Blister53 Gemifloxacin 320mg Tablet 1x5 Blister54 Ivermectin 6 mg Tablet 1x1 Blister55 Ivermectin 6 mg + Albendazole 400mg Tablet 1x1 Blister56 Ketoconazole 200mg Tablet 10 x 10 Alu Alu57 Levofloxacin 500 mg Tablet 10X10 Alu Alu

58 Linzolid 600mg Tablet 1x4Strip Pack

59 Meropenem 1Gm Injection 1X1000 mg Vial

60 Ofloxacin 200 mg Tablet 10X10 Alu Alu61 Ofloxacin 200mg + Ornidazole 500mg Tablet 10X10 Blister62 Ofloxacin 400mg Tablet 10 x 10 Alu Alu

63 Ofloxacin 50 mg/5mlSuspension

30ml Bottle

64 Ofloxacin 50mg + Ornidazole 125mg/5mlSuspension

30ml Bottle

65 Piperacillin 4gm + Tazobactam 0.5gm Injection 1X4.5 gm Vial66 Prulifloxacin 600mg Tablet 10 x 10 Alu Alu67 Quinine Sulphate 300mg Tablet 10x10 Alu Alu68 Roxithromycin 150 mg Tablet 10 x 10 Alu Alu69 Tobramycin 80mg Injection 1X80mg Vial70 Vancomycin 500mg Injection 1X500mg VialCARDIOVASULAR SYSTEM

S.No COMPOSITIONS Type PACK Packing1 Amlodipine 5mg + Atenolol 50mg Tablet 10 x 10 Alu Alu2 Clopidogrel 75mg Tablet 10 x 10 Alu Alu3 Domperidone 10mg + Cinnarizine 20mg Tablet 10X10 Alu Alu

4 Etamsylate 250 mg/2ml Injection1X250 mg

Ampoule

5 Etamsylate 500 mg Tablet 10X10 Alu Alu6 Lisinopril 5mg Tablet 10 x 10 Alu Alu7 Losartan Potassium 50mg Tablet 10 x 10 Alu Alu8 Losartan Potassium 50mg + Amlodipine 5mg Tablet 10 x 10 Alu Alu

9Losartan Potassium 50mg + Hydrochlorothiazide 12.5mg


10Mefenamic Acid 250mg + Tranexamic Acid 500mg


11 Metoprolol 50mg ( Extended Release Cap) Capsules 10 x 10 Blister12 Nebivolol 5mg Tablet 10x10 Alu Alu13 Ramipril 2.5mg Tablet 10 x 10 Alu Alu14 Ramipril 5mg Tablet 10 x 10 Alu Alu15 Ramipril 2.5mg + Hydrochlorothiazide 12.5mg Tablet 10 x 10 Alu Alu

16Telmisartan 40mg + Hydrochlorothiazide 12.5mg


17 Tranexamic Acid 500mg /ml Injection 1X500mg Ampoule18 Trimetazidine 20mg Tablet 10 x 10 Alu Alu

CENTRAL NERVOUS SYSTEM

S.No COMPOSITIONS Type PACK Packing1 Alprazolam 0.25mg + Fluoxetine 20mg Tablet 10X10 Alu Alu2 Alprazolam 0.5mg Tablet 10 x 10 Alu Alu3 Betahistine 16mg Tablet 10 x 10 Alu Alu4 Betahistine 8mg Tablet 10 x 10 Alu Alu5 Clonazepam 0.5mg Tablet 10 x 10 Alu Alu

6Divalproex Sodium Eq. To Valporic Acid 500mg

Tablet 10 x 10 Blister

7 Domperidone 10mg + Paracetamol 500mg Tablet 10 x 10 Blister8 Domperidone 1mg/ml Drop 30ml Bottle

9Doxylamine Succinate 10mg + Pyridoxine 10mg + Folic Acid 0.5mg


10 Escitalopram 10mg Tablet 10 x 10 Alu Alu11 Flunarizine 10mg Tablet 10 x 10 Alu Alu12 Gabapantin 300mg + Methylcobalamin 500mcg Tablet 10 x 10 Alu Alu13 Haloperidol 5mg Tablet 10 x 10 Alu Alu14 Mecobalamin 1000mcg/2ml Injection 10x2ml Ampoule15 Mecobalamin 1500mcg Tablet 10 x 10 Alu Alu16 Mecobalamin 500 mcg + Folic Acid 1500mcg. Syrup 100 ml Bottle

17

Mecobalamin 750mcg + Alpha Lipoic Acid 50mg + Zinc Sulphate 4mg + Vit B1 10mg + Vit B6 3mg + Folic Acid 1.5mg + Niacinamide 50 mg.

Tablet 10x10 Alu Alu

18 Olanzapine 5mg Tablet 10 x 10 Alu Alu19 Ondansetron 2 mg/ml Injection 10x2ml Ampoule

20 Ondansetron 2mg /5mlSuspension

30ml Bottle

21 Ondansetron 4mg Tablet 10X10 Alu Alu22 Pantoprazole 40 mg + Domperidone 10 mg Tablet 10X10 Alu Alu23 Pantoprazole 40 mg + Domperidone 30 mg SR Capsules 10X10 Alu Alu24 Piracetam 500mg Syrup 100ml Bottle25 Piracetam 800mg Tablet 10 x 10 Blister26 Pregabalin 75mg + Methylcobalamin 750Mcg Capsules 10 x 10 Alu Alu27 Promethazine 5mg + Paracetamol 125mg/5ml Suspensio 60ml Bottle

n28 Sertraline 50 mg Tablet 10X10 Alu Alu29 Sertraline 50 mg + Alprazolam 0.25mg Tablet 10X10 Alu Alu

EYE / EAR / NASAL


1Chloramphenicol 5% + Lignocaine 2% + Clotrimazole 1% + Beclomethasone 0.025%

Eye/Ear Drops

5ml Bottle

2 Gatifloxacin 0.3%/5mlEye/Ear Drops

5ml Bottle

3Ketorolac Tromethamine 0.5% + Benzalkonium Chloride 0.02% / 5ml

Eye/Ear Drops

5ml Bottle

4 Moxifloxacin 0.5/ 5mlEye/Ear Drops

5ml Bottle

5 Ofloxacin 0.3% HPMC Eye/Ear Drops

10ml Bottle

6 Tobramycin 0.3% + HPMC Eye/Ear Drops

10ml Bottle

7 Xylometazoline 0.1% /10mlNasal Drops

10ml Bottle

GENITO- URINARY TRACT

S.No COMPOSITIONS Type PACK Packing1 Isoxsuprine 40mg SR Capsules 10 x 10 Blister2 Sildenafil Citrate 50 mg Tablet 10X4 Blister

HORMONES

S.No COMPOSITIONS Type PACK Packing1 Acarbose 50mg Tablet 10 x 10 Blister2 Gliclazide 80mg + Metformin 400mg Tablet 10x10 Blister3 Glimepiride 2mg + Metformin 500mg SR Tablet 10 x 10 Blister4 Hydrocortisone Acetate 100mg Injection 1x100mg Ampoule5 Hydroxyprogesterone 250mg Injection 1x250mg Ampoule

6 Hydroxyprogesterone 500mg Injection1X500mg

Ampoule

7 Metformin 500mg + Pioglitazone 15mg Tablet 10 x 10 Blister8 Nandrolone Decanoate 25mg Injection 1X25mg Blister9 Nandrolone Decanoate 50mg Injection 1X50 mg Blister10 Natural Progesterone 200mg Injection 1x200mg Ampoule

11 Natural Progesterone 100mg Injection1X100mg

Ampoule

12 Natural Progesterone 200mg (Soft Gel)Capsules

10 x 10 Blister

METABOLISM


1 Allopurinol 100mgTABLETS

10 x 10 Blister

2 Atorvastatin 20mgTABLETS

10x10 Alu Alu

3 Atorvastatin 20mg + Ezitamibe 10mg TABLETS

10 x 10 Alu Alu

MUSCULO SKELETAL DISORDER


1Aceclofenac 1.5%W/W + Linseed Oil 3% W/W + Methylsalicylate 10% W/W + Capsailin 0.01 % + Menthol 5% W/W

Gel 30gmLami Tube

2 Aceclofenac 100mg Tablet 10X10 Alu Alu

3 Aceclofenac 150mg /ml Injection1x150mg

Ampoule

4 Aceclofenac 200mg SR Tablet 10X10 Alu Alu5 Aceclofenac 100mg +Paracetamol 500mg Tablet 10X10 Alu Alu

6Aceclofenac 100mg +Paracetamol 500mg + Chlorzoxazone 250mg


7Aceclofenac 100mg +Paracetamol 500mg + Serratiopeptidase 10mg


8 Diacerein 50mg Capsules 10 x 10 Alu Alu

9Diacerein 50mg + Glucosamine Sulphate 750mg


10 Diclofenac Diethylammonium 1.16%w/w + Ointment 30GM Tube

Methyl Salicylate 10%w/w +menthol 5 % w/w + Linseed Oil 3% w/w +Benzyl Alcohol 1%

11Diclofenac Potassium 50 mg + Paracetamol 500mg + Chlorzoxazone 250mg

Tablet 10X10 Blister

12Diclofenac Potassium 50mg + Paracetamol 500mg + Serratiopeptidase 10mg


13Diclofenac Sodium 50mg + Serratiopeptidase 10mg


14 Diclofenac Sodium 75mg/3ml Injection 10x3mlAmpoule

15 Dicyclomine 20mg + Paracetamol 500 mg Tablet 10 x 10 Blister16 Drotaverine 40mg + Mefenamic Acid 250mg Tablet 10 x 10 Blister17 Etoricoxib 90mg Tablet 10 x 10 Alu Alu18 Lornoxicam 8mg Tablet 10 x 10 Alu Alu19 Nimesulide 100mg + Paracetamol 500mg Tablet 10X10 Blister20 Nimesulide 100 mg + Tizanidine 2mg Tablet 10X10 Alu Alu

21Nimesulide 100mg + Serratiopeptidase 10 mg + Paracetamol 500mg


22 Nimesulide 100mg MD Tablet 10 x 10 Alu Alu

23 Nimesulide 50mg + Paracetamol 125mg/5mlSuspension

60ml Bottle

24 Paracetamol 125mg/5mlSuspension

60ml Bottle

25 Paracetamol 500mg Tablet 10 x 10 Blister

26 Tramadol 100 mg/2ml Injection 10x2mgAmpoule

27Tramadol 50 mg + Paracetamol 500 mg + Domperidone 10 mg


28 Tramadol 50mg + Paracetamol 500mg Tablet 10X10 Alu AluNUTRITION


1

Lycopene 8% 2mg + Selenium Dioxide 50mcg + Zinc Sulphate 27.45mg + Vitamin A 2500 I.U. + Vitamin C 50mg + a-Tocopheryl Acetate I.P 10 (I.U)

Capsules 10X10 Blister

2 Ayurvedic Liver Tonic Tonic 200ml Bottle3 Calcium Carbonate 500 mg +Vitamin D3 250

I.U. + Magnesium 40 mg + Manganese 1.8 mg + Tablet 10X10 Blister

Zinc 7.5 mg + Copper 1 mg + Boron 250 mg

4Calcium Carbonate 500mg + Alfacalcidol 0.25 mcg


5Calcium Carbonate 500mg + Calcitrol 0.25Mcg + Zinc 7.5mg


6Carbonyl Iron Eq. To Elementel Iron 100 mg + Folic Acid 1.5mg + Vit. B12 1.5mcg + Vit. C 75mg + Zinc Sulphate Monohydrate 61.8 mg

Capsules 10X10 Blister

7 Cholecalciferol 60000 Iu (1Gm Sachet) Granules 20x1 Sachets

8Cyproheptadine 2mg + Tricholine 275mg Sorbitol Base /10ml

Syrup 200ml Bottle

9Vit B1 5mg + Vit B2 5mg + Vit B6 1.5mg + Vit B12 2.5mcg + Niacinamide 25mg + D-Panthenol 2.5mg + L-Lysine 25mg

Syrup 200 ml Bottle

10 Elemental Calcium 250mg +Vit D3 125I.U.Suspension

200ml Bottle

11Ferric Ammonium Citrate 160mg + Vit. B12 7.5mcg + Elemental Zinc 16.5mg + Folic Acid 0.5 mg

Syrup 200 ml Bottle

12 Ferrous Ascorbate 100mg + Folic Acid 1.5mg Tablet 10 x 10 Alu Alu13 Ferrous Ascorbate 30mg + Folic Acid 550mcg Syrup 150ml Bottle14 Folic Acid 5mg Tablet 4x5x10 Blister

15

Ginseng 42.5mg+ Vit.A 5000 iu + Vit.D3 400iu + Vit B1 6mg+ Vit.B2 5mg + Vit B6 2mg +Vit. B12 5mcg + Vit. C 75mg+ Vit. E 50% 20 I.U.+Calcium Pantothenate 5mg + Niacinamide 45mg + Folic Acid 1.5mg+ Carbonyl Iron 10mg + Pot. Sulphate 10mg + Copper Sulphate 2mcg+ Pot. Iodide 1mg + Manganese Sulphate 1.5mg+ Magnesium Sulphate 30mg+ Zinc Sulphate 2.20mg+ Selenium 40mcg

Capsules 10X10 Alu Alu

16 Iron Sucrose 100mg/ 5ml Injection2.5 & 5ml

Ampoule

17L Ornithine L Aspartate 150mg + Pancreatin 100mg

Tablet 10 x 10 Blister

18 L Ornithine L Aspartate 5gm /10ml Infusion 500 ml Bottle19 Whey Protein 20% 35 G + Carbohydrates 63 G

+ Carbonyl Iron 30mg + Vitamin A 5000 I.U. + Protein Powder

200 gm Tin Box

Vit. C 80mg + Vit D3 300 I.U. + Vit B1 3.3mg + Vit B2 4.5mg + Nicotinamide 50 mg + Calcium Pantothenate 1.6 mg + Vit B6 1.6mg + Folic Acid 10 mg + Vit B12 1.6mcg + Dicalcium Phosphate 1330mg + Copper Sulphate 1.6 mg + Manganese Sulphate 0.1mg

20

Each 100gms contains Protein (20%)-40gm,Carbohydrate-53 gm, Energy Value -375 Kcal, Glutamic Acid -10Mg, L-lysine-25 Mg , Spirulina -100Mg,DHA( Docosahexaenoic Acid)-50Mg, GLA( Gamma linolenic Acid)-120Mg,Vitamin A-3000 i.u , Vitamin D- 300 i.u ,Vitamin B1-3Mg,Vitamin B2-3Mg ,Vitamin B6-2mg,Methycobalamin -100Mcg,Vitamin C-3mcg,Vitamin E- 50mg, Folic Acid-5Mg, Calcium Pantothenate -1mg ,Niacinamide -3mg,Calcium- 30Mg,Phosporus-600mg,Minerals -425mg,Iron-10Mg,Magensium-12Mg,Maganese -5mcg,Copper-2.5mg,Zinc-5mg,Chromium-75mcg,Selenium -60mcg,Sodium-100mg,Potassium-150 mg,Iodine-.01 mg

Protein Powder

200 gm Tin Box

21

Each 100 gm contains (Whey Protein 20 % Powder 30 gm ) Maltodextrin 50 gm milk Powder 10 gm Fat 2 gm Vitamin A 4000 I.U Vitamin C 60mg Vitamin E 5 mg vitamin B1 6 mg vitamin B2 4mg Vitamin D3 500 i.u Calcium D-Pantothenate 6mg Vitamin B6 2 mg Folic Acid 2.5mg Iron 18.5mg calcium 1200 mg Phosphours 660 mg Selenium 200mcg manganese 12 mg Manganese 5 mcg lodine 0.1mg Zinc as Sulphate 1.5mg Excipients qs

Protein Powder

200 gm Tin Box

22 Vit.A 5000 iu + Vit.D3 400iu + Vit B1 6mg+ Vit.B2 5mg + Vit B6 2mg +Vit. B12 5mcg + Vit. C 75mg+ Vit. E 50% 20 I.U.+Calcium Pantothenate 5mg + Niacinamide 45mg + Folic Acid 1.5mg+ Carbonyl Iron 10mg + Pot. Sulphate 10mg + Copper Sulphate 2mcg+ Pot. Iodine 1mg + Manganese Sulphate 1.5mg+

Capsules 10X10 Alu Alu

Magnesium Sulphate 30mg+ Zinc Sulphate 2.20mg+ Selenium 40mcg

OROPHARYNGEAL


1 Chlorhexadine Gluconate 0.2%Mouth wash

100ml Bottle

2Potassium Nitrate 5% + Sodium Monohydrophosphate 0.7%

TOOTH PASTE

50gm Tube

RESIPIRATORY SYSTEM


1Ambroxol 30mg + Terbutaline 2.5mg + Guaiphenesin 100mg +Menthol 2mg

Syrup 100ml Bottle

2Chlorpheniramine Maleate 2mg + Ammonium Chloride 100mg + Sodium Citrate 50mg

Syrup 100ml Bottle

3Dexamethorphan 5mg + Phenylpropanolamine 12.5mg + Chlorpheneramine Maleate 2mg/5ml

Syrup 100ml Bottle

4Diphenhydramine Hcl 14.08mg + Ammonium Chloride 0.138mg + Sodium Citrate 57.03mg + Menthol 1.14mg/5ml

Syrup 100ml Bottle

5 Levocetirizine 5mg + Montelukast 10mg Tablet 10 x 10 Alu Alu

SKIN


1Aloevera 0.1% + Vit E 0.05% + Glycerine 0.1% + Lenoline 0.5%

Soap 75gm

2Beclomethasone 0.025% + Gentamycin 0.1% + Clotrimazole1% Cream Base

Ointment

15gm Tube

3 Clindamycin 1% + Adapalene 0.1% Ointment

15gm Tube

4Gamabenzene Hexa Chloride 1% + Cetrimide 0.01%

Lotion 100ml Bottle

5 Ketoconazole 2% With ZPTO 1% Shampoo

50ml Bottle

6Miconazole Nitrate 2% + Gentamycin Sulphate 0.10%

Ointment

15gm Tube

7 Mometasone Furoate 0.1% w/wOintment

20gm Tube

8 Permethrin 5% Lotion 60ml Bottle

9 Povidone Iodine 5% + Metronidazole 1%Ointment

15gm Tube

10Silver Sulphadiazine 1%w/w + Chlorhexidine Gluconate 0.2% w/w

Ointment

25gm Tube

SURGICAL & VACCINES


1 Serratiopeptidase 10mgTABLETS

10 x 10 Alu Alu

2 Trypsin Chymotrypsin 100000 UnitsTABLETS

10 x 10 Alu Alu

SANIFY HEALTHCARE:-

practices customer satisfaction as its core strength. We believe in capitalising the opportunities through a fair system of dealing. We have our market presence in almost all the


states, be it in the form of franchisees or third party manufacturers.

The company has formed its national network by appointing marketing distributors/franchisees with exclusive monopoly rights (region wise). We have franchisees covering almost all the states with latest product ranges.

This unflagging commitment to quality and customer satisfaction has won the group a high penetration rate in the domestic market and has also carved a significant global niche for its products

Bibliography :-

1. Kotler, Keller, Koshy, and Jha, “Marketing Management”,12th edition, Pearson education publication.

2. NCERT chemistry books.3. Visited www.bioconindia.com4. Visited home sites5. Visited sanifyhealthcare.com.

http://www.bioconindia.com/

Student Profile:-

Name KUMAR RAJEEV

Date of Birth 25 FEBRUARY 1984

Father’s name SHREE ABHIRAM SINGH

Professional Qualification Pursuing PGDM (2009-11) with specialization in Marketing & HR

Name of Institute Business School of Delhi28/1, Knowledge Park-III, Greater Noida Utter Pradesh -201306

Academic Qualification B.Sc. (Hons) I.Sc. Xth

Passing Year

200820011999

University / Board

IGNOU , NEW DELHIBihar Intermediate Educational council Bihar secondary Examination Board

Contact No. +919650173295

Email Id [email protected]

mailto:[email protected]

Documents

final project sanify